财新传媒
财新英文 > 要闻 > 正文

In Depth: China’s First Gene Therapy Struggles to Find Buyers Despite Price Cut

By Cui Xiaotian
2026年10月16日 16:59
Belief BioMed’s hemophilia treatment can work for years after one injection, but insurers and patients are grappling with its upfront cost
Belief BioMed’s hemophilia treatment can work for years after one injection, but insurers and patients are grappling with its upfront cost.

For much of the first half of 2026, Xiao Xiao, the 69-year-old co-founder and chairman of Belief BioMed Co. Ltd., was trying to sell a treatment his company had spent years developing. Xinjiuning is China’s first approved gene therapy for hemophilia, a rare condition that impairs the body’s ability to make blood clots.

  [财新双语通产品,是为有双语需求读者专门订制的优惠产品, 按此可享超值优惠订阅。]

版面编辑:喻竹杨洋
财新网主编精选版电邮 样例
财新网新闻版电邮全新升级!财新网主编精心编写,每个工作日定时投递,篇篇重磅,可信可引。
订阅